PRWEB.COM NewswireDallas, TX (PRWEB) December 06, 2014 The report "Dementia Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Dementia is the loss of psychological features such as considering, storage, and considering that is serious enough to intervene with a person's everyday performing.
Companies discussed in this Dementia Pipeline Review H2 2014 report include Alector LLC, Biotie Therapies Corp., Bristol-Myers Squibb Company, Chase Pharmaceuticals Corporation, Chronos Therapeutics Limited, Echo Pharmaceuticals B.V., FORUM Pharmaceuticals Inc., Hyundai Pharmaceutical Co., Ltd., Ildong Pharmaceutical Co., Ltd., ImStar Therapeutics Inc., Integrative Research Laboratories Sweden AB, Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., Oryzon Genomics S.A., Pacific Northwest Biotechnology, LLC, SK Chemicals Co., Ltd., Stelic Institute & Co., Summit Corporation plc, Sylentis S.A., Tautatis Incorporated, WhanIn Pharmaceutical Co., Ltd.
Drugs profile discussed in this Dementia Pipeline Review H2 2014 report include Antibodies for Dementia and Alzheimer's Disease, Antisense Oligonucleotide to Inhibit microRNA for Neurology, choline alfoscerate SR, CPC-252, dronabinol, Drugs to Agonize c-MET for Dementia, Drugs to Agonize c-MET for Dementia, FRM-0334, GIBH-130, gugulipid, IPN-007, IRL-752, ITI-007, KR-12, Monoclonal Antibodies to Inhibit Tau for CNS Disorders, NAT, NNC-269100, OG-635, Peptide to Inhibit BACE for Cerebropathy and Dementia, RDC-5, RNAi Oligonucleotide for Cerebral Ischemia and Dementia, SID-111, Small Molecule to Activate LPL for CNS and Metabolic Disorders, Small Molecule to Inhibit Glycogene 5 for Dementia, Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases, Synthetic Peptides for Neurological Disorders, TauC3 Monoclonal Antibody, TTT-3002 & WIB-1001C. Order a Purchase copy of this report @ .
... Informe : 2.000 $$ .